Latest news with #Database
ABC News
25-07-2025
- Health
- ABC News
What's behind a spike in adverse event reports for Vyvanse, Australia's biggest ADHD drug?
Australia's pharmaceuticals watchdog is investigating a spike in adverse event reports for Vyvanse, the country's most commonly prescribed ADHD medication. The increase coincides with a leap in prescriptions for ADHD as well as a growing focus on the effectiveness of treatments like Vyvanse on social media. There were 320 adverse event reports relating to Vyvanse — or lisdexamfetamine dimesilate — to the Database of Adverse Event Notifications (DAEN) in the first six months of the year, compared to nine reports in the six months before. The most common adverse events reported were ineffectiveness, anxiety, product labelling issues, therapeutic response decreases and insomnia. The DAEN notes inclusion of an event in the database does not confirm it has been caused by the medication. The World Health Organization's equivalent global database for reporting adverse medicine events has also seen an uptick in reports relating to the active ingredient of Vyvanse, lisdexamfetamine. ADHD is characterised by inattention, hyperactivity and impulsivity. According to a Royal Australian and New Zealand College of Psychiatrists (RANZCP) spokesperson, stimulants, like Vyvanse and Ritalin, appear to normalise some of the brain's main neurotransmitter systems, allowing better regulation of parts of the brain involved in executive function, particularly the frontal lobe. The TGA said its investigations included ongoing independent testing of Vyvanse through TGA laboratories, and that it did not comment on open investigations. "This investigation is the result of a recent increase in adverse event notifications relating to concerns about quality, safety, and reduced effectiveness," a spokesperson said. "Any regulatory actions that arise will be communicated." The TGA also confirmed it had seen an increase in adverse events relating to ADHD-prescribed stimulants more generally, with 754 events registered for the most common drugs — methylphenidate, dexamphetamine and lisdexamfetamine — between January 2015 and June 2025. Only Vyvanse's was significant enough to constitute a safety signal, which is triggered when information suggests a possible causal relationship between adverse events and a drug. "It should be noted that increased usage of a medicine would normally be expected to result in a rise in the number of adverse event reports," the spokesperson said. "Similarly, an uptick in social media commentary would also stimulate reporting." Vyvanse prescriptions almost doubled from 958,831 in 2022 to more than 1.78 million in 2024, according to the Pharmaceutical Benefits Scheme (PBS). RANZCP spokesperson Dr Karuppiah Jagadheesan said an uptick in social media commentary may be contributing to adverse event reporting. Google Trends data shows how much public interest there has been in ADHD and Vyvanse in Australia in recent times, with search volumes and interest in these two search terms both increasing. There are dozens of Reddit threads discussing Vyvanse side effects and effectiveness, and ADHD influencers, whose content ranges from genuine advice to memes, regularly bring the subject up, speaking about their own negative experiences, and encouraging followers to report theirs. Some influencers with tens of thousands of followers have made theories about Vyvanse central to their content. "Social media is very powerful, and certainly there is an element of a shared mindset, and particularly things that are negative can be spread very quickly," Dr Jagadheesan said. Dr Jagadheesan said almost all medications had side effects, and users of Vyvanse should not panic, with adverse events reported by a small percentage of users. He said users should keep taking the medication if it was working for them. "If it's not working adequately or it's wearing off quickly or there are side effects, then they need to talk to their treating doctors, psychiatrist, or GP," he said. He said the RANZCP's committee on ADHD had questioned the effectiveness of Vyvanse at current dosages for some patients, and this may be why ineffectiveness was the most common issue reported to the DAEN. "Sometimes when it doesn't agree with a person it can create side effects like agitation, or even feeling depressed," he said. He said some patients with comorbidities risked mania or psychosis, particularly if they took more than prescribed. Australasian ADHD Professionals Association (AADPA) vice president Dr Sarahn Lovett said the side effects reported for Vyvanse were normal for all stimulants, and she believed a labelling issue on Vyvanse packaging earlier this year had likely contributed to users reporting side effects. The TGA confirmed it previously flagged issues with typos on the drug's packaging, including packaging misspelling "pharmaceutivals", which should have read "pharmaceuticals", and incorrectly pluralising a word so packaging read "each capsules contain". However, the TGA said there were no compliance signals under investigation for the facilities used in manufacturing Vyvanse. Dr Lovett said if Vyvanse was working for a patient, there was no reason to stop taking it, while if it was causing side effects or proving ineffective, users should have a conversation with their prescriber. "The good thing about stimulant medication, however, is that you can stop and start it, so there is no danger to stopping a stimulant — it's just you will no longer be treating your ADHD." Royal Australian College of General Practitioners (RACGP) ADHD spokesperson Tim Jones said the issues went beyond one medication, and adverse event reports aligned with the "pretty astronomical" increase in prescriptions of ADHD stimulants. He said his colleagues in public psychiatry were reporting more mental health admissions related to prescribed stimulants, often triggered by episodes of psychosis, anxiety, and insomnia. "It's something that's certainly entering into serious territory for side effects," Dr Jones said. He said adverse events appear more prevalent among people with complex mental health issues who might have also had an ADHD diagnosis and been started on stimulants. "I think it's a wakeup call to the general safety of stimulants," Dr Jones said. "We do have to have high-quality, balanced discussions with people considering stimulant medications about the relevant positive effects, but also the risk of side effects, because while not common, they are not uncommon either." ADHD Foundation director Christopher Ouizeman said the foundation's helpline had not registered an uptick complaints about Vyvanse. Vyvanse is supplied by Takeda Pharmaceuticals Australia Pty Ltd, and was in the news in early 2024 as Australia suffered months-long shortages of the drug. A Takeda spokesperson said manufacture of Vyvanse was in line with Australia's Therapeutics Goods Act, and strict quality controls were in place. There has been speculation online adverse events began after manufacturing moved to Germany in early 2024. The Takeda spokesperson said the move took place to support increased demand and "there have been no changes to the formulation". Takeda said labelling errors did not impact the quality of the medication.
SBS Australia
23-07-2025
- Business
- SBS Australia
Indigenous Business Boom Connecting Culture and Country
Indigenous businesses have been found to create more than 40 billion dollars in value each year, helping to progress Closing the Gap targets, and leading to stronger connection to culture and country. Data from Austrade shows Indigenous goods exporters generated more than $670 million in turnover in 2022/23. Now a new report from Supply Nation - a non-profit that provides Australia's biggest database of Indigenous businesses - has found that Indigenous businesses create more than 42 billion dollars of social value each year
Time Business News
13-07-2025
- Business
- Time Business News
Beast Your ACA-Database Exam Questions with Reliable ACA-Database PDF Dumps
Are you preparing for the ACA-Database certification exam and searching for the most reliable study material to help you succeed? Look no further! At CertsQuestions, we provide high-quality ACA-Database PDF dumps that are designed to help candidates master their exam with confidence. Whether you're new to Alibaba Cloud or seeking to upgrade your database credentials, our ACA-Database resources offer everything you need to pass your exam on the first attempt. The Alibaba Cloud Certified Associate – Database (ACA-Database) certification is one of the most in-demand credentials in the cloud computing domain. As companies increasingly rely on Alibaba Cloud services, certified professionals are highly sought after for their knowledge of cloud database technologies. Getting certified validates your expertise in database management, architecture, security, and troubleshooting within Alibaba's cloud ecosystem. With ACA-Database certification, you gain a competitive edge in today's cloud-driven job market and enhance your professional profile globally. At CertsQuestions, we understand the pressure of exam preparation. That's why we've created comprehensive ACA-Database PDF dumps that are tailored to match the official exam syllabus. Our dumps include real exam questions with correct answers, verified by industry experts. The ACA-Database exam PDF is updated regularly to reflect the latest changes and patterns in the actual exam, ensuring that you stay one step ahead in your preparation journey. Success in the ACA-Database exam isn't just about memorizing answers—it's about understanding the concepts. Our ACA-Database dumps are accompanied by detailed explanations, allowing you to grasp the 'why' behind every answer. You'll also have access to mock exams and practice modes, which simulate the real test environment. This helps reduce anxiety and boosts your performance under timed conditions. With CertsQuestions, you don't just practice—you master the material. Choosing the right platform for your certification journey can make all the difference. CertsQuestions offers a well-structured, user-friendly platform packed with resources for Alibaba Cloud certification exams. We stand out from the competition by providing: 100% verified questions and answers Regular content updates based on exam changes PDF + web-based practice options 24/7 customer support Money-back guarantee on exam failure Whether you're preparing for the ACA-Database, or exploring other Alibaba Cloud certifications, we're your go-to platform. Understanding your weak areas is key to improving your performance. Our ACA-Database exam dumps not only test your knowledge but also provide performance tracking tools that identify your strengths and weaknesses. This helps you create a targeted study plan, ensuring that you focus on the topics that need the most attention. Our realistic exam simulations mirror the actual Alibaba Cloud ACA-Database interface, so you'll feel confident walking into the exam. Thousands of professionals have already passed the ACA-Database exam using our trusted and effective exam dumps. With CertsQuestions, you can be next! Our materials are tailored to save your time, reduce stress, and deliver maximum exam success. You don't need to waste time searching the internet for outdated materials or second-guessing your preparation. Our ACA-Database dumps give you the right tools to pass with flying colors. If you're serious about passing the ACA-Database certification exam and advancing your career in cloud computing, CertsQuestions is your best companion. With our up-to-date ACA-Database PDF dumps, user-friendly interface, and expert support, you're fully equipped to ace the exam and boost your professional credibility. Don't wait start your ACA-Database preparation now and take a big step toward becoming a certified Alibaba Cloud database professional. TIME BUSINESS NEWS
Cision Canada
10-07-2025
- Business
- Cision Canada
CAE included on TIME Canada's Best Companies 2025 List
MONTREAL, July 10, 2025 /CNW/ - CAE has been included on TIME's list of Canada's Best Companies 2025. This prestigious award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. The award list was announced on July 10 th, 2025, and can be viewed on TIME and Statista identified Canada's Best Companies 2025 based on three dimensions, using more than 15 different criteria for all companies headquartered in Canada that generated over $100 million in revenue. Firstly, employee satisfaction was determined by examining the survey data of over 3 years provided by more than 49,000 employees. Secondly, the revenue growth data from Statista's Growth Database and Company Database were combined to identify the companies with the highest growth. Finally, Environmental, Social, and Governance data, among other standardized KPIs, were combined to get an overall 3 ESG Index for all relevant companies. Based on the results of the study, CAE is honoured to be recognized on TIME's list of Canada's Best Companies 2025. "This recognition is a true testament to the strength of our culture and the remarkable people who bring CAE's purpose to life," said Hélène V. Gagnon, Chief People and Sustainability Officer at CAE. "At CAE, we are all for succeeding together - it's the essence of our One CAE philosophy. It's what drives us to create an environment where every employee is supported, empowered, and inspired to innovate, excel, and realize their full potential." CAE's recently refreshed employee value proposition is anchored in a focused commitment: All for creating meaningful impact. The company continues to uphold this promise by fostering employee well-being and professional growth through a comprehensive range of benefits and inclusive workplace initiatives. Designed to support every stage of an employee's journey, CAE's offerings include flexible vacation policies, enhanced parental leave top-ups, sabbaticals, and robust professional development programs such as leadership training and cross-functional collaboration opportunities. These initiatives are crafted to empower employees to thrive in their careers while maintaining balance in their personal lives. At the heart of CAE's culture is a belief in the power of inclusion. Employees are encouraged to actively shape the company's success, supported by dynamic employee resource groups that foster a sense of belonging. These groups play a vital role in ensuring that every team member feels heard, respected, and valued — creating a workplace where both achievement and personal fulfillment are celebrated. From a business perspective, CAE's disciplined capital deployment and focus on recurring revenue are delivering strong financial performance and attractive incremental returns. By aligning employee engagement and sustainability leadership with business strategy, CAE continues to create shared value for all stakeholders. About Statista Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of the leading data and business intelligence portal that provides statistics, business-relevant data, and various market and consumer studies and surveys. About CAE At CAE, we exist to make the world safer. We deliver cutting-edge training, simulation, and critical operations solutions to prepare aviation professionals and defence forces for the moments that matter. Every day, we empower pilots, cabin crew, maintenance technicians, airlines, business aviation operators, and defence and security personnel to perform at their best and when the stakes are the highest. Around the globe, we're everywhere customers need us to be, with approximately 13,000 employees at around 240 sites and training locations in over 40 countries. For nearly 80 years, CAE has been at the forefront of innovation, consistently seeking to set the standard by delivering excellence in high-fidelity flight simulators and training solutions, while embedding sustainability at the heart of everything we do. By harnessing technology and enhancing human performance, we strive to be the trusted partner in advancing safety and mission readiness - today and tomorrow. Read our FY25 Global Annual Activity and Sustainability Report. CAE Contacts:
Reuters
20-06-2025
- Business
- Reuters
Haveli Investments to buy AI database firm Couchbase for about $1.5 billion
June 20 (Reuters) - Haveli Investments will acquire Couchbase (BASE.O), opens new tab for about $1.5 billion, the companies said on Friday, as the private equity firm looks to capitalize on the artificial intelligence-focused database company's platform. Couchbase's shares, which have gained 21% this year, were up 29% in early trading following the news. The company's cloud-based database powers AI-related applications that need a flexible data model and easy scalability. Couchbase is part of a group of modern database companies — including MongoDB (MDB.O), opens new tab, Cockroach Labs, Snowflake (SNOW.N), opens new tab and Databricks — challenging legacy players such as Oracle (ORCL.N), opens new tab. New database technologies make it easier and faster to store, manage and use a large amount of unstructured data that modern AI systems require. Haveli Investments, founded by former Vista Equity Partners president Brian Sheth, will pay Couchbase shareholders $24.50 per share, which represents a premium of about 29% to the stock's last close price. The private equity firm has a 9.6% stake in Couchbase, according to data compiled by LSEG. It may engage with Couchbase's management or board to explore strategic options, including a potential merger, according to a March filing with the U.S. SEC. The agreement includes a go-shop period that ends on Monday, during which Couchbase can consider alternate offers.
